VTYX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Ventyx Biosciences Inc

NASDAQ | VTYX

6.60

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 23, 2025)

$275.25M

Market Cap

-

P/E Ratio

-1.66

EPS

$4.11

52 Week High

$0.78

52 Week Low

HEALTHCARE

Sector

VTYX Chart

Recent Chart
Price Action

VTYX Technicals

Tags:

VTYX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$1.3M
Total Revenue $0
Cost Of Revenue $1.3M
Costof Goods And Services Sold $1.3M
Operating Income -$148M
Selling General And Administrative $31M
Research And Development $117M
Operating Expenses $148M
Investment Income Net -
Net Interest Income $13M
Interest Income $13M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.3M
Income Before Tax -$135M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$135M
Comprehensive Income Net Of Tax -
Ebit -$135M
Ebitda -$134M
Net Income -$135M

Revenue & Profitability

Earnings Performance

VTYX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $277M
Total Current Assets $230M
Cash And Cash Equivalents At Carrying Value $27M
Cash And Short Term Investments $27M
Inventory -
Current Net Receivables $1M
Total Non Current Assets $47M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $36M
Short Term Investments $190M
Other Current Assets $11M
Other Non Current Assets -
Total Liabilities $23M
Total Current Liabilities $13M
Current Accounts Payable $3.1M
Deferred Revenue -
Current Debt -
Short Term Debt $2.1M
Total Non Current Liabilities $9.7M
Capital Lease Obligations $11M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $11M
Other Current Liabilities $7.5M
Other Non Current Liabilities -
Total Shareholder Equity $254M
Treasury Stock -
Retained Earnings -$554M
Common Stock $7K
Common Stock Shares Outstanding $68M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$131M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.3M
Capital Expenditures $241K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$16M
Cashflow From Financing $122M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$135M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$1.3M
Total Revenue $0
Cost Of Revenue $1.3M
Costof Goods And Services Sold $1.3M
Operating Income -$148M
Selling General And Administrative $31M
Research And Development $117M
Operating Expenses $148M
Investment Income Net -
Net Interest Income $13M
Interest Income $13M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.3M
Income Before Tax -$135M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$135M
Comprehensive Income Net Of Tax -
Ebit -$135M
Ebitda -$134M
Net Income -$135M

VTYX News

VTYX Profile

Ventyx Biosciences Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, dedicated to developing novel small molecule therapeutics for inflammatory and autoimmune disorders. The company is advancing a promising pipeline of drug candidates that target critical pathways involved in these diseases, aiming to meet substantial unmet medical needs. With a robust emphasis on research and development, Ventyx is well-positioned to provide innovative treatment solutions that can improve patient outcomes and capitalize on emerging opportunities within the dynamic biopharmaceutical market.

YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.96%
$12.31
BENF
+205.95%
$1.49
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
TSLA
+2.28%
$448.98
RIG
+14.18%
$3.90
BURU
-5.16%
$0.34
VTYX
+70.98%
$6.60
NOK
+11.26%
$6.17
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.69%
$24.60
MSAI
+101.73%
$1.35
ADAP
-3.44%
$0.07
AAL
+5.62%
$12.77
IONZ
-14.59%
$3.98
EPWK
+13.34%
$0.08
WTO
-5.55%
$0.06
BITF
+4.39%
$4.11
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
DNN
+0.18%
$2.72
IONQ
+7.06%
$59.37
PLUG
-1.36%
$2.88
INTC
+2.50%
$37.84
ABEV
+0.22%
$2.20
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.53%
$38.39
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
SMCI
-9.34%
$47.59
RBNE
+7.87%
$1.37
BBD
+1.51%
$3.35
JOBY
+1.16%
$15.65
VIVK
+5.68%
$0.26
CAN
+3.22%
$1.76
ETHD
-3.29%
$3.96
ACHR
+0.36%
$10.90
RF
-0.14%
$24.07
RMBL
+60.50%
$3.21
SGBX
+29.82%
$2.96
AMD
+2.06%
$234.99
ADD
-25.47%
$0.05
BTG
+0.19%
$5.22
DVLT
-15.41%
$2.14
VLY
+4.24%
$10.56
QS
+8.54%
$14.74
LAES
+5.92%
$5.72
GOOGL
+0.49%
$251.69
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
PFE
-0.20%
$24.67
TNGX
-12.24%
$7.60
AAPL
+0.43%
$259.58
CIFR
+7.10%
$17.25
AMC
-0.90%
$2.72
MARA
+0.36%
$19.22
PLTR
+2.84%
$180.47
ONDS
+5.56%
$7.11
BTBT
+3.06%
$3.70
GPUS
-1.16%
$0.38
HPE
+0.47%
$23.20
IREN
+7.77%
$55.86
UUUU
-6.72%
$21.21
CUTR
-10.19%
$0.09
IBIO
-8.63%
$1.27
PBR
+0.98%
$11.84
NVTS
+0.03%
$13.61
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
LUV
-6.25%
$31.65
TE
-10.46%
$3.68
ETWO
0.00%
$3.30
SCWO
+32.07%
$0.48
SNAP
+1.35%
$7.87
BAC
+1.35%
$51.79
RR
+6.52%
$5.39
BTE
+5.28%
$2.39
WBD
+3.77%
$21.30
APLD
+9.01%
$33.38
DNUT
+1.98%
$4.11
HOOD
+5.58%
$134.33
LUMN
+10.58%
$7.78
BB
-2.80%
$4.51
KMI
-4.26%
$26.38
VALE
-0.52%
$11.46
NIO
+1.24%
$6.92
AFMD
-34.94%
$0.18
NCLH
-0.50%
$23.51
RIVN
+1.35%
$13.09
NAKA
+10.41%
$0.79
KDLY
+10.41%
$0.79
YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.96%
$12.31
BENF
+205.95%
$1.49
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
TSLA
+2.28%
$448.98
RIG
+14.18%
$3.90
BURU
-5.16%
$0.34
VTYX
+70.98%
$6.60
NOK
+11.26%
$6.17
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.69%
$24.60
MSAI
+101.73%
$1.35
ADAP
-3.44%
$0.07
AAL
+5.62%
$12.77
IONZ
-14.59%
$3.98
EPWK
+13.34%
$0.08
WTO
-5.55%
$0.06
BITF
+4.39%
$4.11
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
DNN
+0.18%
$2.72
IONQ
+7.06%
$59.37
PLUG
-1.36%
$2.88
INTC
+2.50%
$37.84
ABEV
+0.22%
$2.20
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.53%
$38.39
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
SMCI
-9.34%
$47.59
RBNE
+7.87%
$1.37
BBD
+1.51%
$3.35
JOBY
+1.16%
$15.65
VIVK
+5.68%
$0.26
CAN
+3.22%
$1.76
ETHD
-3.29%
$3.96
ACHR
+0.36%
$10.90
RF
-0.14%
$24.07
RMBL
+60.50%
$3.21
SGBX
+29.82%
$2.96
AMD
+2.06%
$234.99
ADD
-25.47%
$0.05
BTG
+0.19%
$5.22
DVLT
-15.41%
$2.14
VLY
+4.24%
$10.56
QS
+8.54%
$14.74
LAES
+5.92%
$5.72
GOOGL
+0.49%
$251.69
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
PFE
-0.20%
$24.67
TNGX
-12.24%
$7.60
AAPL
+0.43%
$259.58
CIFR
+7.10%
$17.25
AMC
-0.90%
$2.72
MARA
+0.36%
$19.22
PLTR
+2.84%
$180.47
ONDS
+5.56%
$7.11
BTBT
+3.06%
$3.70
GPUS
-1.16%
$0.38
HPE
+0.47%
$23.20
IREN
+7.77%
$55.86
UUUU
-6.72%
$21.21
CUTR
-10.19%
$0.09
IBIO
-8.63%
$1.27
PBR
+0.98%
$11.84
NVTS
+0.03%
$13.61
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
LUV
-6.25%
$31.65
TE
-10.46%
$3.68
ETWO
0.00%
$3.30
SCWO
+32.07%
$0.48
SNAP
+1.35%
$7.87
BAC
+1.35%
$51.79
RR
+6.52%
$5.39
BTE
+5.28%
$2.39
WBD
+3.77%
$21.30
APLD
+9.01%
$33.38
DNUT
+1.98%
$4.11
HOOD
+5.58%
$134.33
LUMN
+10.58%
$7.78
BB
-2.80%
$4.51
KMI
-4.26%
$26.38
VALE
-0.52%
$11.46
NIO
+1.24%
$6.92
AFMD
-34.94%
$0.18
NCLH
-0.50%
$23.51
RIVN
+1.35%
$13.09
NAKA
+10.41%
$0.79
KDLY
+10.41%
$0.79
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.